Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

Tekijä Chang, Ih, Muralidharan, Kumar Kandadi, Campbell, Nolan, Ho, Pei‐Ran
Julkaisussa J Clin Pharmacol (2020)

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay

Tekijä Campagnolo, Denise, Dong, Qunming, Lee, Lily, Ho, Pei-Ran, Amarante, Diogo, Koendgen, Harold
Julkaisussa J Neurovirol (2016)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Tekijä Butzkueven, Helmut, Licata, Stephanie, Jeffery, Douglas, Arnold, Douglas L, Filippi, Massimo, Geurts, Jeroen JG, Santra, Sourav, Campbell, Nolan, Ho, Pei-Ran
Julkaisussa BMJ Open (2020)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Tekijä Butzkueven, Helmut, Kappos, Ludwig, Wiendl, Heinz, Trojano, Maria, Spelman, Tim, Chang, Ih, Kasliwal, Rachna, Jaitly, Seema, Campbell, Nolan, Ho, Pei-Ran, Licata, Stephanie
Julkaisussa J Neurol Neurosurg Psychiatry (2020)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Tekijä Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei-Ran, Beck Jensen, Jens-Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B
Julkaistu 2013

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Tekijä Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Julkaisussa Neurology (2019)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Tekijä Plavina, Tatiana, Muralidharan, Kumar Kandadi, Kuesters, Geoffrey, Mikol, Daniel, Evans, Karleyton, Subramanyam, Meena, Nestorov, Ivan, Chen, Yi, Dong, Qunming, Ho, Pei-Ran, Amarante, Diogo, Adams, Alison, De Sèze, Jerome, Fox, Robert, Gold, Ralf, Jeffery, Douglas, Kappos, Ludwig, Montalban, Xavier, Weinstock-Guttman, Bianca, Hartung, Hans-Peter, Cree, Bruce A.C.
Julkaisussa Neurology (2017)